Clearside Biomedical (CLSD) – Globe Newswire
-
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
-
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
-
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
-
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
-
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
-
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
-
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
-
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
-
Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting
-
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®
-
Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
-
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD
-
Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023
-
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
-
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in
-
Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit
-
Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference
-
Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
-
Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023
-
Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023
-
Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientif
-
Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings
-
Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
-
Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023
-
Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema
-
Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
-
Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update
-
Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference
-
Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023
-
Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
-
Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
-
Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
-
Clearside Biomedical to Participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference
-
Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal Physicians
-
Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023
-
Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings
-
Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023
-
Clearside Biomedical Announces Leadership Team Update
-
Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD
-
Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022
-
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
-
Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
-
Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patien
-
Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results
-
Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022
-
Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform
-
Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
-
Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022
Back to CLSD Stock Lookup
